Open Access. Powered by Scholars. Published by Universities.®

Women's Health Commons

Open Access. Powered by Scholars. Published by Universities.®

Breast cancer

Minnesota State University, Mankato

Articles 1 - 2 of 2

Full-Text Articles in Women's Health

Choosing Between Medical Surveillance And Preventive Surgical Interventions Among Asymptomatic Brca Positive Women, Hillary Zupan Jan 2021

Choosing Between Medical Surveillance And Preventive Surgical Interventions Among Asymptomatic Brca Positive Women, Hillary Zupan

All Graduate Theses, Dissertations, and Other Capstone Projects

Women with a known BRCA 1 or BRCA 2 genetic mutation are at an increased risk for the development of cancer, most commonly breast and uterine types. Risk reduction strategies to manage cancer risk include increased medical surveillance and various preventive surgeries. This is a deeply personal decision and one that is influenced by a variety of factors. The aim of this literature review is to identify the key factors impacting the decision-making process of a woman with a BRCA mutation and how a woman ultimately decides between the cancer risk management strategies. Six electronic databases were used to obtain …


Safety And Efficacy Of Bioidentical Hormone Therapy In Menopause: A Literature Review, Kathryn Akre Jan 2021

Safety And Efficacy Of Bioidentical Hormone Therapy In Menopause: A Literature Review, Kathryn Akre

All Graduate Theses, Dissertations, and Other Capstone Projects

Vasomotor symptoms (VMS) experienced during menopause can negatively impact a woman’s quality of life, productivity, sleep, and mood. Systemic hormone therapy (HT) is the most effective treatment for moderate to severe VMS, however safety concerns raised by the 2002 Women’s Health Initiative (WHI) trial have led to a decrease in overall HT use and a growing demand for custom-compounded bioidentical HT. Misconceptions regarding the superior safety and efficacy of custom-compounded hormones and lack of clinician expertise in menopause management contribute to ongoing uncertainty and low uptake of United States (U.S.) Food and Drug Administration (FDA) approved bioidentical HT products. This …